Showing results (161-170 of 174) with videos related to
Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 TrialThomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE TrialElena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.The New England Journal of Medicine|June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis, Olivia Pagani, Gini F Fleming, et al.Breast Cancer Research : BCR|April 25, 2014
International study on inter-reader variability for circulating tumor cells in breast cancerMichail Ignatiadis, Sabine Riethdorf, François-Clement Bidard, et al.Pageof 18